Maria Carmen
Maria Carmen Antolin Mate, Sant Cugat Del Valles (barcelona) ES
Patent application number | Description | Published |
---|---|---|
20150368283 | D-FAGOMINE FOR THE CONTROL OF INFLAMMATORY PROCESSES RELATED TO AN OVERACTIVATION OF THE HUMORAL IMMUNE RESPONSE - The present invention belongs to the field of nutraceuticals or functional agents with immunostimulating capacity for triggering mechanisms of the innate immune response at a mucosal level. More specifically, it refers to the use of the compound | 12-24-2015 |
Maria Carmen Arilla Rodriguez, Bilbao ES
Patent application number | Description | Published |
---|---|---|
20150152148 | HYPOALLERGENIC HYBRID PROTEINS OF MAJOR GROUP 1 AND 2 MITE ALLERGENS FOR USE IN THE TREATMENT OF ALLERGIES - The present invention refers to recombinant AND molecules coding to hybrids polypeptides of different allergens from | 06-04-2015 |
Maria Carmen Arilla Rodriguez, Bizkaia ES
Patent application number | Description | Published |
---|---|---|
20110052640 | HYPOALLERGENIC HYBRID PROTEINS OF MAJOR GROUP 1 AND 2 MITE ALLERGENS FOR USE IN THE TREATMENT OF ALLERGIES - The present invention refers to recombinant ADN molecules coding to hybrids polypeptides of different allergens from | 03-03-2011 |
Maria Carmen Artal Lahoz, Zaragoza ES
Patent application number | Description | Published |
---|---|---|
20110272397 | HOB HAVING AT LEAST ONE HEATING ZONE HAVING SEVERAL HEATING ELEMENTS - A hob includes at least one heating zone having several heating elements, a user interface for setting a heating capacity of the heating zone, and a control unit for operating the heating elements and for distributing the heating capacity among the heating elements according to a heating capacity distribution. In order to improve the efficiency of the hob, the control unit is configured to distribute the heating capacity among a larger number of heating elements when the heating capacity is below a threshold value than in the case, when the heating capacity is above the threshold value. | 11-10-2011 |
20120024835 | COOKTOP HAVING A DETECTION ASSEMBLY AND METHOD FOR OPERATING A COOKTOP - A cooktop includes a plurality of heating elements, a user interface for inputting a power level, a detection assembly for detecting a position and size of at least one cookware element, and a control unit designed to combine a plurality of heating elements into a heating zone depending on the detected size and position of the cookware element and to operate the heating elements of the heating zone with a total heat output. In order to ensure a reproducible total heat output, the control unit is designed to calculate a bottom surface of the cookware element from the measurands of the detection assembly and to determine the total heat output depending on power level and bottom surface. | 02-02-2012 |
20150322572 | Method for Passivating a Metal Surface - A method for passivating a metal surface including, generating an atmospheric plasma beam by electrical discharge in a working gas, introducing an acid-containing passivating agent into the plasma beam, applying the plasma beam containing the passivating agent the metal surface, and depositing a passivating salt on the metal surface by a reaction between the acid-containing passivating agent and the metal surface. This method simplifies the process for passivating a metal surface and renders it more effective. | 11-12-2015 |
Maria Carmen Belinchon Vergara US
Patent application number | Description | Published |
---|---|---|
20110194459 | REGISTRATION OF PRIVATE USER IDENTITIES AND CONTACT ADDRESSES IN AN IMS NETWORK - The present invention faces the issues of registering more than one IMPI and more than one contact address within a single registration procedure in an IMS network. Thus, the present invention provides for a method and a HSS to allow the implicit registration of more than one IMPI, or the implicit registration of more than one contact address, or both, upon explicit registration of a subscriber with a given IMPI/IMPU pair and a given contact address. In particular, the invention provides for a method including the steps of configuring subscriber data for the subscriber at the HSS with at least one implicit registration set selected from: a set of IMPI's associated with a given IMPI or with a given IMPU, and a set of contact addresses per IMPI basis; downloading from the HSS towards the S-CSCF the implicit registration set; and building up a corresponding data model therein. | 08-11-2011 |
Maria Carmen Benitez Ortuzar, Granada ES
Patent application number | Description | Published |
---|---|---|
20110153326 | SYSTEM AND METHOD FOR COMPUTING AND TRANSMITTING PARAMETERS IN A DISTRIBUTED VOICE RECOGNITION SYSTEM - A system and method for extracting acoustic features and speech activity on a device and transmitting them in a distributed voice recognition system. The distributed voice recognition system includes a local VR engine in a subscriber unit and a server VR engine on a server. The local VR engine comprises a feature extraction (FE) module that extracts features from a speech signal, and a voice activity detection module (VAD) that detects voice activity within a speech signal. The system includes filters, framing and windowing modules, power spectrum analyzers, a neural network, a nonlinear element, and other components to selectively provide an advanced front end vector including predetermined portions of the voice activity detection indication and extracted features from the subscriber unit to the server. The system also includes a module to generate additional feature vectors on the server from the received features using a feed-forward multilayer perceptron (MLP) and providing the same to the speech server. | 06-23-2011 |
Maria Carmen Berasain Lasarte, Pamplona (navarra) ES
Patent application number | Description | Published |
---|---|---|
20120220546 | COMPOSTIONS DESIGNED FOR THE INHIBITION AND/OR BLOCKING OF THE EPITHELIAL/MESENCHYMAL TRANSITION - 5′-methylthioadenosine (MTA) is described as a compound that is susceptible to inhibiting and/or blocking the epithelial-mesenchymal transition (EMT), a process whereby epithelial cells become mesenchymal cells. | 08-30-2012 |
Maria Carmen Boix Bernardini, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20120014918 | ADDITION SALTS OF AMINES CONTAINING HYDROXYL AND/OR CARBOXYLIC GROUPS WITH AMINO NICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS - The present disclosure is directed to novel water-soluble pharmaceutically acceptable, crystalline addition salts of (i) an amine containing one or more hydroxyl and/or carboxylic groups with (ii) amino nicotinic acid derivatives of formula (I) | 01-19-2012 |
20120245359 | PROCESS FOR MANUFACTURING 2-[(3,5-DIFLUORO-3'-METHOXY-1,1'-BIPHENYL-4 YL)AMINO]NICOTINIC ACID - The present disclosure relates to a process for manufacturing 2-[(3,5-difluoro-3′-methoxy-1,1′biphenyl-4-yl)amino]nicotinic acid. | 09-27-2012 |
Maria Carmen Garcia-Alegre Sánchez, Madrid ES
Patent application number | Description | Published |
---|---|---|
20100059045 | TWO-AXIS HYDRAULIC SOLAR TRACKER - A two-axis solar tracker that orientates and adjusts the angular position of associated solar collector panels. The tracker may be hydraulically operated all movements of the tracker may be produced by three hydraulic cylinders. | 03-11-2010 |
Maria Carmen Garcia-Alegre Sánchez, Madrid ES
Patent application number | Description | Published |
---|---|---|
20100059045 | TWO-AXIS HYDRAULIC SOLAR TRACKER - A two-axis solar tracker that orientates and adjusts the angular position of associated solar collector panels. The tracker may be hydraulically operated all movements of the tracker may be produced by three hydraulic cylinders. | 03-11-2010 |
Maria Carmen Pardina Palleja, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20140194448 | TRANSVAGINAL PHOSPHODIESTERASE INHIBITORS FOR INFERTILITY TREATMENT - The present invention relates to a new application of phosphodiesterase inhibitors for couple infertility treatment which forms an effective alternative to the invasive assisted reproductive techniques such as conjugal artificial insemination and which consists of the transvaginal administration of a phosphodiesterase inhibitor immediately before and/or after coitus. It also relates to dosage forms suitable for the intravaginal administration of phosphodiesterase inhibitors. | 07-10-2014 |
Maria Carmen Pumar Duran, Leioa-Vizcaya ES
Patent application number | Description | Published |
---|---|---|
20100004283 | 4-[(3-FLUOROPHENOXY)PHENYLMETHYL]PIPERIDINE METHANESULFONATE: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS - The present patent application is directed to 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonic acid salt (formula I), its synthesis and use in the manufacture of a medicament for the treatment and/or prevention of a serotonine and/or norepinephrine mediated disease or condition. The present invention is also directed to pharmaceutical compositions comprising the same. | 01-07-2010 |
Maria Carmen Valcarce Lopez, Oak Ridge, NC US
Patent application number | Description | Published |
---|---|---|
20110313007 | USE OF METFORMIN IN COMBINATION WITH A GLUCOKINASE ACTIVATOR AND COMPOSITIONS COMPRISING METFORMIN AND A GLUCOKINASE ACTIVATOR - The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator. | 12-22-2011 |
20140066372 | Glucokinase Activator Compositions for the Treatment of Diabetes - The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment. | 03-06-2014 |
20140100218 | Treatment of Mild and Moderate Alzheimer's Disease - The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4- | 04-10-2014 |
20150072985 | USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY - The present invention provides methods for treating muscle atrophy by administering a PPARδ agonist. | 03-12-2015 |
20150313908 | Combinations of a GLP1R Agonist and Metformin and Use Thereof for the Treatment of Type 2 Diabetes and Other Disorders - The present invention provides uses of a glucagon-like peptide 1 receptor agonist in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GLP1R agonist and metformin. | 11-05-2015 |
Maria Carmen Valcarce-Lopez, Limhamn SE
Patent application number | Description | Published |
---|---|---|
20090216013 | Heteroaryl-Ureas and Their Use as Glucokinase Activators - This invention relates to compounds of formula (I) | 08-27-2009 |
20100204288 | Heteroaryl-Ureas and Their Use as Glucokinase Activators - This invention relates to compounds of formula (I) | 08-12-2010 |
20110060019 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS - This invention relates to compounds of formula (I) | 03-10-2011 |
20110301158 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS - This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. | 12-08-2011 |
María Carmen Ardanuy Tisaire, L'Hospitalet De Llobregat ES
María Carmen Ardanuy Tisaire, L'Hospitalet De Llobregat ES
María Carmen Blanco Varela, Santiago De Compostela ES
Patent application number | Description | Published |
---|---|---|
20100215766 | USE OF ATOMIC QUAMTUM CLUSTER (AQC) AS ANTIMICROBIAL AGENTS AND BIOCIDES - The invention relates to the use of stable atomic quantum clusters (AQC) with antimicrobial activity. The stable AQCs include at least 500 metal atoms (Mn, n<500), the metals being selected from among Au, Ag, Co, Cu, Pt, Fe, Cr, Pd, Ni, Rh, Pb or bi- or multi-metallic combinations thereof. Said AQCs are used as antimicrobial agents, antifungal agents and biocides at concentrations of the order of between 1 nM and 100 nM or more in relation to atoms of the corresponding metal. The antimicrobial activity is specific to both the type of metal and size of cluster used. | 08-26-2010 |
María Carmen Blanco Varela, Santiago De Compostela ES
Patent application number | Description | Published |
---|---|---|
20100215766 | USE OF ATOMIC QUAMTUM CLUSTER (AQC) AS ANTIMICROBIAL AGENTS AND BIOCIDES - The invention relates to the use of stable atomic quantum clusters (AQC) with antimicrobial activity. The stable AQCs include at least 500 metal atoms (Mn, n<500), the metals being selected from among Au, Ag, Co, Cu, Pt, Fe, Cr, Pd, Ni, Rh, Pb or bi- or multi-metallic combinations thereof. Said AQCs are used as antimicrobial agents, antifungal agents and biocides at concentrations of the order of between 1 nM and 100 nM or more in relation to atoms of the corresponding metal. The antimicrobial activity is specific to both the type of metal and size of cluster used. | 08-26-2010 |
María Carmen Lara Ruiz, Sevilla ES
Patent application number | Description | Published |
---|---|---|
20150297613 | USE OF AGENTS THAT ALTER THE PERITUMORAL ENVIRONMENT FOR THE TREATMENT OF CANCER - The invention relates to the use of agents that alter the peritumoral environment, specifically non-peptide NK1 receptor antagonists, for the treatment of cancer. The peritumoral environment is formed by the stromal cells, the stromal matrix, intra- and peri-tumoral vascularization and the cells responsible for the inflammatory and/or immune response around the tumor. The result of the alteration to the peritumoral environment is a reduction in the size of the tumor, the prevention of its development and, optionally, the induction of its disappearance. The invention also relates to pharmaceutical compositions containing said peritumoral-environment-altering agents, either alone or combined with at least one other active ingredient, for the treatment of cancer. | 10-22-2015 |